MUC19 and non-small cell lung carcinoma: Of particular interest for treatment personalisation is the fact that NSCLC with MUC19 mutations responds very well to anti-PD1 inhibitors [67], making this particular gene interesting to study in the context of checkpoint inhibitor therapy for HPV+ OPSCC.